Zobrazeno 1 - 10
of 192
pro vyhledávání: ''
Autor:
Said Akli, Amriti R. Lulla, Taylor T. Chrisikos, Marc A. Pina, Stephanie S. Watowich, Yifan Zhou, Haiyan S. Li, Khandan Keyomarsi
Publikováno v:
Cancer Research. 80:P3-10
Background: Chronic inflammation, a hallmark of cancer, is associated with poor prognosis in human various malignancies. Predominantly, tumor associated neutrophils (TANs) and myeloid-derived suppressor cells (MDSCs) are immune cells well characteriz
Publikováno v:
Cancer Research
The crosstalk between cancer cells and the immune system is crucial for disease progression and its therapeutic targeting is providing exciting results, in particular with newly developed immune checkpoint inhibitors. Current approaches primarily foc
Publikováno v:
Cancer Res
Chromosomal instability (CIN) is one of the major forms of genomic instability in various human cancers and is recognized as a common hallmark of tumorigenesis and heterogeneity. However, some malignant tumors show a paucity of chromosomal alteration
Autor:
Helen Piwnica-Worms, Cullen M. Taniguchi, Anirban Maitra, Sonal Gupta, Meifang Yu, Amit Deorukhkar, Marimar de la Cruz Bonilla, Yanqing Huang, Charles V. Kingsley, Laura Baseler, Daniel Lin, Lauren E. Colbert, Eugene J. Koay, Tara N. Fujimoto, Gabriel O. Sawakuchi, Jessica M. Molkentine, Peter K. Cabeceiras, Ramesh C. Tailor
Publikováno v:
Cancer Res
When pancreatic cancer cannot be removed surgically, patients frequently experience morbidity and death from progression of their primary tumor. Radiation therapy (RT) cannot yet substitute for an operation because radiation causes fatal bleeding and
Autor:
Francois Richard, M.J. Piccart, G Rouas, D. Larsimont, Diether Lambrechts, David R. Brown, Giancarlo Pruneri, Florian Clatot, S Majjaj, Bram Boeckx, C Desmedt, G. Van den Eynden, Caterina Marchiò, Françoise Rothé, Anne Vincent-Salomon, Odette Mariani, Christos Sotiriou, Christine Galant, Julien Pingitore, François Bertucci, Roberto Salgado
Publikováno v:
Cancer Research. 79:GS1-06
Background: Invasive lobular breast cancer (ILC) represents the second most common histology of breast cancer, accounts for 10-15% of all invasive cases and generally expresses the estrogen receptor (ER, coded by the ESR1 gene). Little is known about
Autor:
Teresa Pirozzi, Tea Teresa Iavazzo, Maria Mangini, Donatella Delle Cave, Annachiara De Luca, Annalisa Di Domenico, Gennaro Andolfi, Enza Lonardo
Publikováno v:
Cancer Research. 81:PO-038
Pancreatic ductal adenocarcinoma (PDAC) is a devastating and essentially incurable disease, typically characterized by high chemoresistance and metastatic spread attributable to cancer stem cells (CSCs). This subpopulation is critical for tumor initi
Publikováno v:
Cancer Research. 81:1778-1778
In the tumor microenvironment (TME), innate and adaptive immune populations produce inflammatory cytokines that, while often critical for anti-tumor immunity, also mediate tumor-promoting functions. This paradoxical role of inflammation highlights th
Autor:
Kazuki Sudo, Shigemasa Takamizawa, Tadaaki Nishikawa, Tatsunori Shimoi, Kan Yonemori, Shu Yazaki, Tomoyasu Kato, Yuki Kojima, Hiroshi Yoshida, Rui Kitadai
Publikováno v:
Cancer Research. 81:657-657
Background: The folate receptor alpha (FRα) is a glycosyl-phosphatidylinositol-anchored membrane protein that binds and internalizes folate for purine and thymidine DNA biosynthesis, repair, and methylation. FRα have a role in cellular migration an
Autor:
MT Pombo, MV Costanzo, Carolina Ponce, R. D. Chacon, Adrian Nervo, Pablo Mandó, Verónica Fabiano, C Perez de la Puente, Carlos Martin Loza, M Maino, Jorge Nadal, Manglio Rizzo, Federico Coló
Publikováno v:
Cancer Research. 77:P6-09
Introduction: Breast cancer is the tumor with highest incidence and mortality in women in Argentina. Hormonal receptors (HR) and HER2 are the most important prognostic and predictive factors. It is suggested that estrogen receptors (ER), progesterone
Autor:
Christina Yau, Christopher C. Benz, Alexander D. Borowsky, CK Thompson, Linda S. Lindström, Kamila Czene, LJ Esserman, Bo Nordenskjöld, Tommy Fornander, O Stål, L.J. van 't Veer
Publikováno v:
Cancer Research. 77:P2-05
Background We and others have shown that the clinically used breast cancer markers alter their expression throughout tumor progression, influencing patient survival (Lindström et al, JCO 2012). What are the likely explanations to our findings? Here,